Relmada Therapeutics, Inc. (RLMD) on Monday announced positive 12-month interim results from its Phase 2 trial evaluating NDV-01 for high-risk non-muscle invasive bladder cancer.
The bladder cancer treatment achieved a 76 percent complete response rate at 12 months, with an 80 percent response rate among patients with BCG-unresponsive disease.
The therapy also showed a favorable safety profile, with no progression to muscle-invasive disease and no patients requiring radical cystectomy. NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel designed for simplified in-office administration.
Based on the results, Relmada plans to advance NDV-01 into the Phase 3 RESCUE registrational program, expected to begin in mid-2026, targeting both BCG-unresponsive and intermediate-risk NMIBC patient groups.
RLMD is currently trading at $5.89 up $1.44 or 32.33 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.